Stay updated on Lonca Tesirine + Ibrutinib in Lymphoma Clinical Trial

Sign up to get notified when there's something new on the Lonca Tesirine + Ibrutinib in Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Lonca Tesirine + Ibrutinib in Lymphoma Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    6 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a change in the number of participants enrolled in the Phase 1/2 study evaluating the safety and efficacy of Loncastuximab Tesirine in combination with Ibrutinib for participants with Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma.
    Difference
    0.1%
    Check dated 2024-06-06T14:35:13.000Z thumbnail image
  7. Check
    20 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying age, health conditions, and prior treatments required for inclusion in the study. Previously, no information was provided for collaborators and investigators.
    Difference
    36%
    Check dated 2024-05-22T21:22:16.000Z thumbnail image
  8. Check
    42 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2024-04-30T22:14:22.000Z thumbnail image

Stay in the know with updates to Lonca Tesirine + Ibrutinib in Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Lonca Tesirine + Ibrutinib in Lymphoma Clinical Trial page.